Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Pancreatic Neoplasms 1Pancreatic Ductal Adenocarcinoma 1Osteosarcoma 1Colorectal Neoplasms 1Breast Neoplasms 1

Interventions

X-Rays 5Phantoms, Imaging 5Magnetic Resonance Spectroscopy 5Nuclear Medicine Department, Hospital 4Cyclophosphamide 4fludarabine 3Specimen Handling 3Gemcitabine 3Doxorubicin 3Biopsy 3ulixertinib 2tipifarnib 2selpercatinib 2olaparib 2larotrectinib 2ivosidenib 2ensartinib 2cabozantinib 2Methotrexate 2Mesna 2Ifosfamide 2Eflornithine 2Cisplatin 2tazemetostat 1talazoparib 1selinexor 1pazopanib 1palbociclib 1mifamurtide 1merphos 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Osteosarcoma × Hydroxychloroquine × 30 days × Clear all
NCT03598595 2026-05-14

Gemcitabine, Docetaxel, and Hydroxychloroquine in Treating Participants With Recurrent or Refractory Osteosarcoma

M.D. Anderson Cancer Center

Phase 1/2 Active not recruiting
31 enrolled
Sarcoma

Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡